Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP).
PURPOSE: To evaluate the usefulness of manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate) (Mn-DPDP) in magnetic resonance (MR) imaging of cirrhotic livers. MATERIALS AND METHODS: Fifty-eight patients (mean age, 58.8 years), 29 with and 29 without cirrhosis, underwent MR imaging before and after intravenous administration of 5 mumol/kg Mn-DPDP. Enhancement effects were assessed quantitatively and qualitatively. Histologic confirmation was obtained in 51 patients. RESULTS: Liver parenchyma in both patient groups enhanced significantly on T1-weighted spin-echo and gradient-recalled-echo (GRE) images (P < .01). However, cirrhotic livers enhanced significantly less than noncirrhotic livers on T1-weighted GRE images (P < .05). Fourteen cirrhotic livers had heterogeneous enhancement of parenchyma; enhancement was more prominent on GRE images. Decreased enhancement was seen in patients with confluent fibrosis (n = 5), diffuse fibrosis (n = 6), and siderotic regenerating nodules (n = 4). Increased enhancement was seen in patients with benign regenerating nodules (n = 4). CONCLUSION: Mn-DPDP is useful in patients with cirrhosis.[1]References
- Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP). Murakami, T., Baron, R.L., Federle, M.P., Peterson, M.S., Oliver, J.H., Davis, P.L., Confer, S.R. Radiology. (1996) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
